H.C. Wainwright raised the firm’s price target on Adagene (ADAG) to $8 from $5 and keeps a Buy rating on the shares. The company presented positive data from its ongoing Phase 1/2 study with ADG126, the analyst tells investors in a research note. The firm says safety and repeat dosing could be the differentiating factors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue